Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.73 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.67 |
| ▸ | LDLR | P01130 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 5/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL1133104 | 0.94 | HPGDS (0.67) | HPGDSPCSK9LDLRIDO1CYP11B1 | |
| SCHEMBL21128683 | 0.87 | IDO1 (0.68) | HPGDSPCSK9LDLRIDO1CYP11B1 | |
| SCHEMBL2315186 | 0.85 | HPGDS (1.00) | HPGDSPCSK9LDLRIDO1CYP11B1 | |
| SCHEMBL31627317 | 0.82 | CYP2A6 (0.62) | HPGDSPCSK9LDLRIDO1CYP1A2 | |
| SCHEMBL1133225 | 0.82 | CYP2A6 (0.62) | HPGDSPCSK9LDLRIDO1CYP1A2 | |
| SCHEMBL1502339 | 0.81 | IDO1 (0.51) | HPGDSPCSK9LDLRIDO1CYP11B1 | |
| SCHEMBL24185698 | 0.79 | IDO1 (0.50) | HPGDSPCSK9LDLRIDO1 | |
| SCHEMBL10985317 | 0.79 | IDO1 (0.53) | HPGDSPCSK9LDLRIDO1 | |
| SCHEMBL5779888 | 0.79 | IDO1 (0.50) | HPGDSPCSK9LDLRIDO1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28862527 | 0.79 | IDO1 (0.50) | HPGDSPCSK9LDLRIDO1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276767-B | Sweat-resistant knitted fabric and preparation method thereof | 广东兆天纺织科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-114276767-A | Sweat-resistant knitted fabric and preparation method thereof | 广东兆天纺织科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| WO-2026047630-A1 | HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS | HETERO LABS LIMITED (IN) | 2026-03-05 | — | — | WO | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025128834-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11926625-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4301756-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-0532177-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5550136-A | ANTAGONISTS OF DOPAMINE D-2 RECEPTORS | ZENECA LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| US-5399568-A | Dopamine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-21 | — | — | US | disclosed |
| EP-0532177-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
| CN-1014710-B | PROCESS FOR 6-BETA (SUBSTRATED)-SHYDROXYMETHYL-PENICILLANIC ACID AND ITS DERIVATIVES | PFIZER (US) | 1991-11-13 | — | — | CN | disclosed |
| US-4782050-A | BACTERICIDES | PFIZER INC. (US) | 1988-11-01 | — | — | US | disclosed |
| CN-88100588-A | The preparation method of 6-β (replacement)-(S)-methylol-penicillanic acid and their derivative | — | 1988-08-10 | — | — | CN | disclosed |
| EP-0276942-A1 | 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1988-08-03 | — | — | EP | disclosed |
| EP-0007672-A1 | Isocyanoalkenes, process and useful intermediates for their preparation, pharmaceutical and fungicidal preparations containing those isocyanoalkenes and the use of the fungicidal preparations in agriculture | GIST-BROCADES N.V. (NL) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HPGDS 174/4885PCSK9 314/4885LDLR 1265/4885 |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | HPGDS 1062/4885PCSK9 991/4885LDLR 4268/4885 |
| US-11926625-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | HPGDS 174/4885PCSK9 314/4885LDLR 1265/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | HPGDS 972/4885PCSK9 4000/4885LDLR 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.